ArticleMedicina (Kaunas, Lithuania)2026
Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study.
Sedat Biter, Ertuğrul Bayram, Tolga Köşeci, Mehmet Cihan İçli, Ahmet Melih Arslan, Faruk Recep Özalp, Nadiye Sever, Ahmet Ünsal, Nargiz Majidova Altuntaş, Mustafa Seyyar and 12 more
Abstract readMulticenter Study
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Sedat BiterDepartment of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaras 46050, Türkiye.ORCID 0000-0002-1053-0668 Ertuğrul BayramDepartment of Medical Oncology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.ORCID 0000-0001-8713-7613 Tolga KöşeciDepartment of Medical Oncology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.
Mehmet Cihan İçliDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye.ORCID 0000-0002-7857-6902 Ahmet Melih ArslanDepartment of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, Izmir 35340, Türkiye.ORCID 0000-0002-6126-4611 Faruk Recep ÖzalpDepartment of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, Izmir 35340, Türkiye.ORCID 0000-0002-2863-3243 Nadiye SeverDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Türkiye.ORCID 0000-0001-7312-3827 Ahmet ÜnsalDepartment of Medical Oncology, Faculty of Medicine, Yeditepe University, Istanbul 34755, Türkiye.ORCID 0000-0001-8625-0761 Nargiz Majidova AltuntaşDepartment of Medical Oncology, VM Medicalpark Maltepe Hospital, Istanbul 34846, Türkiye.ORCID 0000-0002-2575-5819 Gülhan DinçDepartment of Medical Oncology, Hatay Training and Research Hospital, Hatay 31060, Türkiye.
Mahmut BüyükşimşekDepartment of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana 01260, Türkiye.ORCID 0000-0001-6356-9059 Mehmet TürkerDepartment of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana 01260, Türkiye.ORCID 0000-0003-4163-917X Şendağ YaslıkayaDepartment of Medical Oncology, Giresun Training and Research Hospital, Giresun 28200, Türkiye.
Yasemin Aydınalp CamadanDepartment of Medical Oncology, University of Health Sciences, Şanlıurfa Mehmet Akif İnan Training and Research Hospital, Sanlıurfa 63300, Türkiye.ORCID 0000-0003-2435-368X Umut KefeliDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye.
Mehmet UzunDepartment of Medical Oncology, University of Health Sciences, İzmir Tepecik Training and Research Hospital, Izmir 35180, Türkiye.ORCID 0000-0002-8596-4233 Hasan Çağrı YıldırımDepartment of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Türkiye.ORCID 0000-0003-3060-377X Hüseyin Salih SemizDepartment of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, Izmir 35340, Türkiye.ORCID 0000-0002-7083-8517 Mustafa ErmanDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye.
İsmail Oğuz KaraDepartment of Medical Oncology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.ORCID 0000-0003-4963-2028 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Renal CellKidney NeoplasmsNivolumabAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCohort StudiesC-Reactive ProteinFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsRetrospective StudiesSerum AlbuminAntineoplastic Agents, ImmunologicalC-Reactive ProteinNivolumabSerum AlbuminalbuminbiomarkerC-reactive proteinmodified Glasgow Prognostic Scorenivolumabprognosisrenal cell carcinomasystemic inflammation
Identifiers
PMID42796282
PMCPMC13608985
What OpenQuestion holds
Textmetadata
Read underepoch 390